Ad
Friday, 1 June 2018
Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod
ZURICH (Reuters) - Novartis's generics unit on Friday won a European panel's recommendation for its biosimilar version of AbbVie's Humira as the Swiss drugmaker aims to take a bite out of sales of one of the world's best-selling medicines.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment